The findings that individuals with metastatic prostate cancer had a greater prevalence of germline mutations in DNA repair genes such as BRCA2, ATM, CHEK2, BRCA1, rad51d, and PALB2 than patients with local illnesses is a promising study field for discovering disease risk levels in gene testing (Pritchard et al. 2016).Future study will discover how gene mutations alter and customize therapy choices, as well as describe the clinical importance of these gene mutations. This evidence concerns the gene PALB2 and metastatic prostate carcinoma.